OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

The combination of TriMixDC-MEL and ipilimumab produced durable tumor responses in patients with pretreated advanced melanoma, according to a phase II study.

In light of the recent announcement by Vice President Joe Biden to infuse the US cancer research program with $1 billion, a so-called “Moon Shot” program, we are speaking today with Giulio Draetta, a clinician and cancer researcher at MD Anderson Cancer Center at the University of Texas in Houston, who leads that center’s Moon Shots program.

The PD-1‒targeting drug nivolumab combined with stereotactic radiation may work synergistically and help improve overall survival while resulting in minimal neurotoxicity in brain metastatic melanoma patients.

Somatic immune system gene variants predict the survival time of patients with cutaneous melanoma, and might augment existing clinical and pathologic prognostic tools, report researchers at New York University’s Langone Medical Center and Perlmutter Cancer Center.

Dose-determining phase I clinical trials may not correctly determine the appropriate doses of small molecule oncology drugs to administer in larger, later stage trials.

Researchers at Oregon State University (OSU) are reporting that they have come up with a new nanotech drug delivery system that may combat melanoma in a whole new way.

A 32-year-old woman presents with a cutaneous nodule and a biopsy is performed. What is your diagnosis?


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.